Protein Summary
Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic su ...more
- ENST00000257904
- ENSP00000257904
- ENSG00000135446
- CMM3
- PSK-J3
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
chemical | 1 | ||
kinase perturbation | 1 | ||
interacting protein | 0.99 | ||
molecular function | 0.99 | ||
drug perturbation | 0.96 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2941.76 (req: < 5)
Gene RIFs: 359 (req: <= 3)
Antibodies: 995 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2941.76 (req: >= 5)
Gene RIFs: 359 (req: > 3)
Antibodies: 995 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 37
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 526
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 4